investorscraft@gmail.com

Intrinsic Value of Ascendis Pharma A/S (ASND)

Previous Close$159.40
Intrinsic Value
Upside potential
Previous Close
$159.40

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2022-12-31 and quarterly data as of 2023-09-30.

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year(a)2023202420252026202720282029203020312032203320342035203620372038203920402041204220432044204520462047

INCOME STATEMENT

Revenue growth rate, %485.9NaN
Revenue, $54NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m646NaN
Operating income, $m-592NaN
EBITDA, $m-573NaN
Interest expense (income), $mNaN
Earnings before tax, $m-609NaN
Tax expense, $m6NaN
Net income, $m-614NaN

BALANCE SHEET

Cash and short-term investments, $m775NaN
Total assets, $m1148NaN
Adjusted assets (=assets-cash), $m373NaN
Average production assets, $m148NaN
Working capital, $m793NaN
Total debt, $m536NaN
Total liabilities, $m871NaN
Total equity, $m277NaN
Debt-to-equity ratio1.930NaN
Adjusted equity ratio-1.261NaN

CASH FLOW

Net income, $m-614NaN
Depreciation, amort., depletion, $m19NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m-522NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-5NaN
Free cash flow, $m-517NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m793
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount